IP Library › Granted Patent US 12,625,281
Granted Patent B2
US 12,625,281 · App. 18/774,022 · Granted May 12, 2026

System and method for the detection of gamma radiation from a radioactive analyte and providing real time administration feedback

Inventors: Joshua G. Knowland (Cary, NC); Charles W. Scarantino (Raleigh, NC); Ronald K. Lattanze (Morrisville, NC); Steve Perrin (Durham, NC)
Assignee: Lucerno Dynamics, LLC
G01T1/161A61B6/4258A61B6/463G01T1/1612G01T1/1648A61B6/467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,625,281
App. No.
18/774,022
Granted
May 12, 2026
Kind
B2
Abstract

A system and method for the measurement of radiation emitted from an in-vivo administered radioactive analyte. Gamma radiation sensors may be used to determine the proper or improper administration of a radioactive analyte, and provide real time feedback to an autoinjector or other administration device or person. The feedback may include identification of an infiltration event and/or a likelihood that an infiltration event resulted in a radiation dose to a patient above a certain value, among other things.

Claims (40)

1 . A system for providing real-time feedback to an auto-injection system during administration of a radioactive analyte that decays in vivo, the system comprising:

at least one ex vivo gamma radiation measurement sensor to detect gamma radiation and to produce signal data, the ex vivo measurement sensor adapted to sensing gamma radiation proximate to a point of administration of the radioactive analyte on a subject;

a signal amplifier in operable communication with the gamma radiation sensor, the signal amplifier adapted to amplify the signal data;

at least one computer processor and a non-transient memory, the computer processor in operable communication with the non-transient memory and the amplified signal data;

wherein the non-transient memory includes computer program code executable by the at least one computer processor, the computer program code configured for performing the steps of receiving the amplified signal data, accessing reference data corresponding to an administration protocol, comparing the amplified signal data to the reference data to determine a likelihood of improper administration of the radioactive analyte to the subject, and communicating an administration status to the auto-injection system.

2 . The system of claim 1 , wherein the radioactive analyte being administered is a therapeutic drug or a diagnostic drug.

3 . The system of claim 1 , wherein the administration protocol comprises one or more protocols for placement of one or more of the at least one sensors, administration location, analyte injection rate, analyte injection dose, analyte administration device, type of radioactive analyte being administered, needle gauge used to administer the radioactive analyte, one or more patient characteristics, and saline line flush.

4 . The system of claim 3 , wherein the one or more patient characteristics comprise one or more of patient weight, height, age, body-mass index, patient sex, patient hydration, patient movement during administration, blood pressure, and blood-glucose.

5 . The system of claim 1 , wherein the administration status comprises a presence or absence of an infiltration.

6 . The system of claim 5 , wherein the administration status comprises a likelihood that infiltrated radioactive analyte will result in a radiation dose to the subject above a predetermined value.

7 . The system of claim 1 , wherein the administration status comprises a presence or absence of the radioactive analyte at an intended location.

8 . The system of claim 1 , wherein the amplified signal data is transmitted from a measurement sensor output.

9 . A method for providing real-time feedback to an auto-injection system during administration to a subject of a radioactive analyte that decays in vivo, the method comprising:

(i) applying at least one ex vivo gamma radiation measurement sensor proximate to a point of administration on the subject of the radioactive analyte;

(ii) detecting gamma radiation over a desired period of time and producing signal data associated with the desired period of time;

(iii) amplifying the signal data using a signal amplifier in operable communication with the ex vivo gamma radiation measurement sensor and outputting the amplified signal data;

(iv) processing the amplified signal data using a computer processor in operative communication with a non-transient memory by performing the steps of:

(a) receiving the amplified signal data associated with the desired period of time;

(b) from the non-transient memory, accessing reference administration factors and reference data distributed over a reference period of time;

(c) comparing the amplified signal data to the reference data and reference administration factors to determine a likelihood of improper administration of the radioactive analyte to the subject; and

(d) communicating an administration status to the auto-injection system.

10 . The method of claim 9 wherein the reference administration factors comprise one or more of an identity of an individual overseeing administration of the radioactive analyte, a method of administration of the radioactive analyte, a dose of radioactive analyte administered, a type of radioactive analyte, a type of autoinjector device used to administer radioactive analyte, an amount of time the autoinjector device used to administer radioactive analyte is in place, a needle gauge used to administer the radioactive analyte, a flush volume used in conjunction with the administration of the radioactive analyte, a location of administration of the radioactive analyte, an orientation of administration of the radioactive analyte, a type of patient therapy, and one or more patient characteristics.

11 . The method of claim 10 , wherein the patient characteristics comprise one or more of patient weight, height, age, body-mass index, patient sex, patient hydration, patient movement during administration, blood pressure, and blood-glucose.

12 . The method of claim 9 further comprising receiving one or more patient administration factors and comparing the one or more patient administration factors to the reference data and reference administration factors for determining the likelihood of improper administration of the radioactive analyte to the subject.

13 . The method of claim 12 wherein the patient administration factors comprise one or more of an identity of an individual overseeing administration of the radioactive analyte, a method of administration of the radioactive analyte, a dose of radioactive analyte administered, a type of radioactive analyte, a type of autoinjector device used to administer radioactive analyte, an amount of time the autoinjector device used to administer radioactive analyte is in place, a needle gauge used to administer the radioactive analyte, a flush volume used in conjunction with the administration of the radioactive analyte, a location of administration of the radioactive analyte, an orientation of administration of the radioactive analyte, a type of patient therapy, and one or more patient characteristics.

14 . The method of claim 13 , wherein the patient characteristics comprise one or more of patient weight, height, age, body-mass index, patient sex, patient hydration, patient movement during administration, blood pressure, and blood-glucose.

15 . The method of claim 9 , wherein the administration status comprises a presence or absence of an infiltration.

16 . The method of claim 15 , wherein the administration status comprises a likelihood that infiltrated radioactive analyte will result in a radiation dose to the subject above a predetermined value.

17 . The method of claim 9 , wherein the administration status comprises a presence or absence of the radioactive analyte at an intended location.

18 . A method for providing real-time feedback to an administrator of a radioactive analyte that decays in vivo to a subject, the method comprising:

(i) applying at least one ex vivo gamma radiation measurement sensor proximate to a point of administration on the subject of the radioactive analyte;

(ii) detecting gamma radiation over a desired period of time and producing signal data associated with the desired period of time;

(iii) amplifying the signal data using a signal amplifier in operable communication with the ex vivo gamma radiation measurement sensor and outputting the amplified signal data;

(iv) processing the amplified signal data using a computer processor in operative communication with a non-transient memory by performing the steps of:

(a) receiving the amplified signal data associated with the desired period of time;

(b) from the non-transient memory, accessing reference administration factors and reference data distributed over a reference period of time;

(c) comparing the amplified signal data to the reference data and reference administration factors to determine a likelihood of improper administration of the radioactive analyte to the subject; and

(d) communicating an administration status to the administrator.

19 . The method of claim 18 wherein the reference administration factors comprise one or more of an identity of an individual overseeing administration of the radioactive analyte, a method of administration of the radioactive analyte, a dose of radioactive analyte administered, a type of radioactive analyte, a type of autoinjector device used to administer radioactive analyte, an amount of time the autoinjector device used to administer radioactive analyte is in place, a needle gauge used to administer the radioactive analyte, a flush volume used in conjunction with the administration of the radioactive analyte, a location of administration of the radioactive analyte, an orientation of administration of the radioactive analyte, a type of patient therapy, and one or more patient characteristics.

20 . The method of claim 18 further comprising receiving one or more patient administration factors and comparing the one or more patient administration factors to the reference data and reference administration factors for determining the likelihood of improper administration of the radioactive analyte to the subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2026
From: LUCERNO DYNAMICS, LLC
To: RADNOSTIX, INC.
Reel/Frame 075944/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2024
From: KNOWLAND, JOSHUA G.; SCARANTINO, CHARLES W.; LATTANZE, RONALD K.; PERRIN, STEVE
To: LUCERNO DYNAMICS, LLC
Reel/Frame 067998/0200 →
Continuity (7)
Continuation 18142382 · May 2, 2023
Continuation 17083875 · Oct 29, 2020
Continuation 15885112 · Jan 31, 2018
Division 14678550 · Apr 3, 2015
Continuation In Part 13840925 · Mar 15, 2013
Provisional Application 61653014 · May 30, 2012
Related Publication 20240369719A1 · Nov 7, 2024
References Cited (43)
US 4629894A · Lelong · 1986 [cited by applicant]
US 4692890A · Arseneau · 1987 [cited by applicant]
US 4881171A · Jatteau et al. · 1989 [cited by applicant]
US 5007427A · Suzuki et al. · 1991 [cited by applicant]
US 5309357A · Stark et al. · 1994 [cited by applicant]
US 5428223A · Jatteau et al. · 1995 [cited by applicant]
US 5583343A · Dilmanian et al. · 1996 [cited by applicant]
US 5647363A · Rabito et al. · 1997 [cited by applicant]
US 5821538A · De Antoni et al. · 1998 [cited by applicant]
US 6448544B1 · Stanton · 2002 [cited by examiner]
US 6668544B1 · Baerts · 2003 [cited by applicant]
US 8680476B2 · Webster · 2014 [cited by examiner]
US 20020137991A1 · Scarantino et al. · 2002 [cited by applicant]
US 20030012731A1 · Suddarth · 2003 [cited by examiner]
US 20030189657A1 · Hammadou · 2003 [cited by applicant]
US 20050143927A1 · Cammia et al. · 2005 [cited by applicant]
US 20050287065A1 · Suddarth et al. · 2005 [cited by applicant]
US 20060076523A1 · Higashllsogawa et al. · 2006 [cited by applicant]
US 20090150315A1 · Wirtz et al. · 2009 [cited by applicant]
US 20090226915A1 · Guyon · 2009 [cited by applicant]
US 20090250602A1 · Black et al. · 2009 [cited by applicant]
US 20090266993A1 · Baerwolff et al. · 2009 [cited by applicant]
US 20100010343A1 · Daghighian · 2010 [cited by examiner]
US 20100198061A9 · Daghighian et al. · 2010 [cited by applicant]
US 20100268078A1 · Scarantino et al. · 2010 [cited by applicant]
US 20110196234A1 · Buono · 2011 [cited by examiner]
US 20110301863A1 · Auribault et al. · 2011 [cited by applicant]
US 20140018675A1 · Keppel · 2014 [cited by examiner]
JP 2002196080 · 2002 [cited by applicant]
WO 2007140352 · 2007 [cited by applicant]
WO 2009158143 · 2009 [cited by applicant]
WO 2010039298 · 2010 [cited by applicant]
Extended European Search Report dated Nov. 11, 2016. [cited by applicant]
S.D. Wollenweber, R.D. Hichwa, and L.L.B. Ponto, “A Simple On-Line Arterial Time-Activity Curve Detector for [0-15] Water PET Studies”, IEEE Transactions on Nuclear Science, vol. 44, No. 4, pp. 1613-1617, Aug. 1997. [cited by applicant]
Son, C . . . An Impaintable Wireless Microdosimeter for Radiation Oncology, School of Electrical and computer Engineering, Mems 2008, Jan. 13-17, 2008, pp. 256-259. [cited by applicant]
Basak Abhishek, Low-Power Implantable Ultrasound Imager for Online Monitoring of Tumor Growth, 33rd Annual Intl Conference of the IEEE EMBS, Boston, MA, Aug. 30-Sep. 3, 2011, pp. 2858-2861. [cited by applicant]
Weber, A. Wolfgang, Use of PET for monitoring Cancer Therapy and for Predicting Outcome, The Journal of Nuclear Medicine, vol. 46, No. 6, Jun. 2005 pp. 983-995. [cited by applicant]
Delbeke, Dominique, Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0, The Journal of Nuclear Medicine, vol. 47, No. 5, May 2006, pp. 885-895. [cited by applicant]
Dunnwald, Lisa, PET Tumor Metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: Value of static versus kinetic measuring of flurodeoxyglucose uptake, Clinical Cancer Research, vol. 1… [cited by applicant]
Velasqquez, Linda M., Repeatability of 18F-FDG PET in a multicenter Phase I study of patients with advanced gastrointestinal malignancies, The Journal of Nuclear Medicine, vol. 50, No. 10, Oct. 2009, pp. 1646-1654. [cited by applicant]
International Search Report dated Feb. 19, 2014. [cited by applicant]
Osman, Medhat M., FOG dose extravasatins in PET/CT: frequency and impact on SUV measurements, Front Oncol, Nov. 16, 2011, http://journal.frontiersin.org/article/10.3389/fonc.2011.0004/full. [cited by applicant]
Office Action dated Aug. 15, 2014. [cited by applicant]